By Ross Neitz, University of Alberta...
In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary...
海角社区 Newsroom...
RSS